Crispr Therapeutics AG (CRSP) AI Stock Analysis

• Market Cap: $5.21B
• Dividend Yield: N/A
• Average Volume (3M): 1.57M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: -81.10%
• EPS Growth: -99.21%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 95,300,230
• 10 Day Avg. Volume: 1,737,104
• 30 Day Avg. Volume: 1,569,970
• PEG Ratio: -0.07
• Price to Book (P/B): 1.72
• Price to Sales (P/S): 94.87
• P/FCF Ratio: -22.95
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 137.16
• Enterprise Value/Gross Profit: -38.60
• Enterprise Value/Ebitda: -9.52
• 1Y Price Target: $68.93
• Price Target Upside: 27.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $56.00 ▲(3.21% Upside)

The score is held back primarily by weak financial performance (deep losses, negative gross profit, and significant cash burn), partially offset by a relatively solid balance sheet. Technicals are neutral-to-mildly positive, while valuation is constrained by loss-making status and no dividend support.

Positive Factors

Innovative Gene Editing Platform

The development of the SyNTase platform for gene editing represents a significant advancement in CRISPR's technology, potentially leading to new treatments for genetic disorders. This innovation could enhance the company's competitive edge in the biotechnology sector.

Strategic Collaborations

Strategic partnerships with established pharmaceutical companies provide Crispr Therapeutics with financial resources and enhance its R&D capabilities. These collaborations can accelerate product development and commercialization, supporting long-term revenue growth.

Advancement in Clinical Trials

Progress in clinical trials, such as the dosing of the first patient in a Phase 2 trial, indicates advancement in CRISPR's pipeline. Successful trials can lead to new product approvals and market entry, driving future revenue and market position.

Negative Factors

Negative Profitability

Crispr Therapeutics' ongoing negative profitability poses a challenge to its financial stability. Sustained losses can limit reinvestment in R&D and expansion, potentially impacting long-term growth and competitive positioning.

Revenue Decline

A significant decline in revenue growth indicates challenges in generating sales from existing products or collaborations. This trend could hinder the company's ability to fund ongoing R&D and affect its market competitiveness.

Cash Flow Challenges

Negative cash flows highlight sustainability concerns, as the company may struggle to cover operational expenses without external funding. This situation could limit strategic investments and slow down product development.

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

How the Company Makes Money

Crispr Therapeutics generates revenue through several key streams. The primary source of income comes from partnerships and collaborations with other pharmaceutical and biotechnology companies, which often involve upfront payments, milestone payments, and royalties on sales of products developed using Crispr's technology. Additionally, the company may earn revenue through licensing agreements for its proprietary technology. As therapies progress through clinical trials and receive regulatory approvals, potential commercialization can lead to significant revenue through product sales. Furthermore, research grants and investments can also contribute to the company's financial resources.

Crispr Therapeutics AG Financial Statement Overview

Summary

Balance sheet strength (low leverage; sizable equity base) is outweighed by very weak operating fundamentals: negative gross profit, large operating losses, and substantial cash burn (negative operating cash flow and free cash flow). Revenue growth is strong but appears volatile and not yet translating into sustainable profitability.

Income Statement

TTM (Trailing-Twelve-Months) revenue is up sharply (+248%), but profitability is very weak: gross profit is negative and operating losses remain large (EBIT about -$574M) with a deeply negative net margin (about -1,252%), indicating high costs relative to the current revenue base. Results have also been volatile year-to-year (e.g., strong profitability in 2021 followed by heavy losses in subsequent periods), which reduces earnings quality and visibility despite the recent top-line rebound.

Balance Sheet

The balance sheet appears relatively solid for a biotech: leverage is low with debt-to-equity around 0.13 in TTM (Trailing-Twelve-Months), and equity remains sizable (~$1.92B) versus total assets (~$2.25B). The key weakness is returns—TTM (Trailing-Twelve-Months) return on equity is meaningfully negative (~-25%) due to ongoing losses, which can pressure the capital base over time if cash burn persists.

Cash Flow

Cash generation is currently a clear concern: TTM (Trailing-Twelve-Months) operating cash flow is about -$302M and free cash flow is about -$303M, with free cash flow declining versus the prior period. A positive offset is that free cash flow and net income move closely (free cash flow is roughly in line with net loss), suggesting losses are not being masked by large non-cash gains—however, the absolute level of cash burn remains high.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.75M	35.00M	370.00M	436.00K	913.08M	719.00K
Gross Profit	-130.60M	-75.25M	239.75M	-109.81M	811.90M	-268.69M
EBITDA	-529.50M	-447.31M	-202.70M	-648.99M	391.48M	-345.25M
Net Income	-488.30M	-366.25M	-153.61M	-650.17M	377.66M	-348.87M
Balance Sheet
Total Assets	2.25B	2.24B	2.23B	2.24B	2.75B	1.83B
Cash, Cash Equivalents and Short-Term Investments	1.92B	1.90B	1.69B	1.82B	2.38B	1.69B
Total Debt	211.02M	223.69M	238.63M	244.02M	225.03M	61.43M
Total Liabilities	329.33M	309.95M	346.77M	367.58M	352.42M	163.73M
Stockholders Equity	1.92B	1.93B	1.88B	1.88B	2.40B	1.66B
Cash Flow
Free Cash Flow	-303.14M	-144.68M	-269.85M	-532.93M	457.27M	-256.72M
Operating Cash Flow	-302.49M	-142.77M	-260.38M	-495.74M	538.97M	-238.37M
Investing Cash Flow	36.82M	-280.48M	374.65M	-258.65M	-1.04B	-541.17M
Financing Cash Flow	326.49M	331.98M	62.66M	38.59M	250.94M	1.02B

Crispr Therapeutics AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 54.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Negative. The current price of 54.26 is below the 20-day moving average (MA) of 55.18, below the 50-day MA of 54.87, and above the 200-day MA of 53.10, indicating a neutral trend. The MACD of -0.13 indicates Positive momentum. The RSI at 47.31 is Neutral, neither overbought nor oversold. The STOCH value of 38.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRSP.

Crispr Therapeutics AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BEAM	53 Neutral	$3.14B	-6.92	-47.19%	―	-84.07%	-157.71%
NTLA	52 Neutral	$1.62B	-3.48	-52.11%	―	33.52%	21.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APLS	50 Neutral	$2.78B	73.46	14.10%	―	42.11%	―
CRSP	50 Neutral	$5.21B	-9.72	-25.33%	―	-81.10%	-99.21%
LEGN	50 Neutral	$3.50B	-13.99	-22.60%	―	74.91%	31.54%
KYMR	50 Neutral	$5.61B	―	-32.09%	―	-50.05%	-54.47%

Crispr Therapeutics AG Corporate Events

CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies

On January 12, 2026, CRISPR Therapeutics issued an update on its pipeline, underscoring progress across in vivo gene editing, cell therapy and regenerative medicine programs. In 2025, the company reported positive Phase 1 data for CTX310, showing deep and durable reductions in triglycerides and LDL cholesterol after a single IV dose with a favorable safety profile, and has moved the ANGPTL3-targeting therapy into Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia. CTX320, targeting LPA, has yielded up to 73% reductions in the dose-escalation phase, while next-generation LPA candidate CTX321, designed with a more potent guide RNA and the same LNP platform, is in IND/CTA-enabling studies alongside CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency, reflecting a broadening cardiovascular and metabolic portfolio. The company also highlighted progress for its CAR-T candidate zugocabtagene geleucel (zugo-cel) in autoimmune diseases and B-cell malignancies, with early systemic lupus erythematosus data showing sustained drug-free clinical remission and B-cell depletion in heavily pretreated patients, and an expanded oncology strategy via a collaboration with Eli Lilly to test zugo-cel with pirtobrutinib in aggressive B-cell lymphomas. In regenerative medicine, CRISPR Therapeutics reported promising 12‑month C-peptide data from diabetes candidate CTX211 that are guiding a shift toward next-generation hypoimmune cell therapy CTX213, which has shown strong preclinical efficacy and is being advanced toward clinical testing, signaling the company’s intent to consolidate its position as a leading player in gene-edited therapies across multiple high-need disease areas.

The most recent analyst rating on (CRSP) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.